Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 13

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 13
---
 risk factor contained below.

| • |     | We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability. |

| • |     | We may need substantial additional funding to allow us to support through clinical development and commercial launch, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. |

| • |     | Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. |

| • |     | We are a clinical stage biopharmaceutical company and have a limited operating history upon which to base an investment decision. |

| • |     | We will face intense competition and may not be able to compete successfully. |

| • |     | We may incur substantial product liability or indemnification claims relating to the use of our product candidates |

| • |     | Our product candidates are at an early stage of development and may not be successfully developed or commercialized. |

| • |     | Any product candidates we advance into and through clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. |

| • |     | If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. |

| • |     | Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval. |

| • |     | If we breach our license or other intellectual property-related agreements for our product candidates or otherwise experience disruptions to our business relationships with our licensor, we could lose the ability to continue the development and commercialization of our product candidates. |

| • |     | Our success will depend upon intellectual property, proprietary technologies and regulatory market exclusivity periods, and we may be unable to protect our intellectual property. |

| • |     | We may not realize the anticipated benefits from the Kineta Merger. |

**Investing in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, the section of this prospectus entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and